Publications
Detailed Information
Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, D H | - |
dc.contributor.author | Kim, S-W | - |
dc.contributor.author | Suh, C | - |
dc.contributor.author | Lee, J-S | - |
dc.contributor.author | Lee, J H | - |
dc.contributor.author | Lee, S-J | - |
dc.contributor.author | Ryoo, B Y | - |
dc.contributor.author | Park, K | - |
dc.contributor.author | Kim, J S | - |
dc.contributor.author | Heo, D S | - |
dc.contributor.author | Kim, N K | - |
dc.date.accessioned | 2010-01-12T02:09:52Z | - |
dc.date.available | 2010-01-12T02:09:52Z | - |
dc.date.issued | 2007-09-08 | - |
dc.identifier.citation | Ann Oncol. 2008 Jan;19(1):123-7. Epub 2007 Sep 6. | en |
dc.identifier.issn | 1569-8041 (Electronic) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17823384 | - |
dc.identifier.uri | https://hdl.handle.net/10371/29577 | - |
dc.description.abstract | BACKGROUND: Belotecan (Camtobell, Chong Keun Dang Corp, Seoul, Korea; CKD602) is a new camptothecin analogue. This study aimed to investigate the safety and efficacy of single-agent belotecan for small-cell lung cancer (SCLC). PATIENTS AND METHODS: Twenty-seven patients with chemotherapy-naive or chemosensitive SCLC were treated with belotecan 0.5 mg/m(2)/day on days 1-5 of a 3-week cycle. All 27 patients were assessable for toxicity, and 21 patients assessable for response. RESULTS: Nine patients (42.9%) showed objective tumor responses including one complete response; seven (63.6%) in 11 chemotherapy-naive patients; and two (20.0%) in 10 chemosensitive patients. With a median follow-up of 5 years, median progression-free and survival time for chemotherapy-naive patients were 4.8 months and 11.9 months, respectively, while the corresponding values for chemosensitive patients were 3.3 months and 10.5 months, respectively. The most common toxicity was neutropenia. CONCLUSION: Belotecan was active in SCLC patients as a single agent, warranting further investigations of belotecan in combination with platinum or other active agents. | en |
dc.language.iso | en | en |
dc.publisher | Oxford University Press | en |
dc.subject | Aged | en |
dc.subject | Antineoplastic Agents, Phytogenic/pharmacokinetics/*therapeutic use | en |
dc.subject | Antineoplastic Combined Chemotherapy Protocols/therapeutic use | en |
dc.subject | Camptothecin/adverse effects/*analogs & | en |
dc.subject | derivatives/pharmacokinetics/therapeutic use | en |
dc.subject | Carcinoma, Small Cell/*drug therapy | en |
dc.subject | DNA Topoisomerases, Type I/antagonists & inhibitors | en |
dc.subject | Disease-Free Survival | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Lung Neoplasms/*drug therapy | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasm Proteins/antagonists & inhibitors | en |
dc.subject | Neutropenia/chemically induced | en |
dc.subject | Salvage Therapy | en |
dc.subject | Treatment Outcome | en |
dc.title | Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study | en |
dc.type | Article | en |
dc.identifier.doi | 10.1093/annonc/mdm437 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.